Author

Valerie Pivorunas 1

1 AbbVie Bioresearch Center,Worcester,United States

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante, Valerie Pivorunas, James Butler, Naim Mahi, Nael M. Mostafa, Melanie Ruzek, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Florian Rieder, Julian Panés, Jean-Frédéric Colombel

EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Marc Ferrante, Xiaomei Liao, Yinuo Pang, Valerie Pivorunas, Tadakazu Hisamatsu

MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

Julian Panés, Bram Verstockt, Valerie Pivorunas, James Butler, Naim Mahi, Melanie Ruzek, Thierry Sornasse, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Azucena Salas, Nick Kennedy, Tariq Ahmad, Severine Vermeire

Item 1 - 3 / 3
1